AmpliPhi Recieves Positive FDA Feedback for its Bacteriophage Candidate AB-PA01 Development Plans Targeting Pseudomonas Aeruginosa Infections

AmpliPhi Recieves Positive FDA Feedback for its Bacteriophage Candidate AB-PA01 Development Plans Targeting Pseudomonas Aeruginosa Infections

Source: 
CP Wire
snippet: 
  • Company received positive written response from FDA regarding development plans
  • Resistant P. aeruginosa is designated as ‘Priority 1: Critical’ pathogen by the World Health Organization